The exercise period for warrants of series TO3 starts today

Today, November 2, 2023 the exercise period for warrants of series TO3 begins in PEPTONIC medical AB ("Peptonic" or the "Company"). The exercise period lasts until November 16, 2023.

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.

 

Summarized terms for the warrants of series TO3:

Exercise period: November 2, 2023 – November 16, 2023.

Issue size: 196,370,600 warrants of series TO3, which entitles to subscription of 196,370,600 shares. If all warrants are exercised, the Company will receive approximately SEK 9.8 million before issuing costs.

Exercise price: SEK 0.05 per share.

Last day for trading warrants of series TO3: November 13, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK
4,909,265.00, from SEK 29,379,492.23 to SEK 34,288,757.23. If all warrants are exercised the number of shares in the Company will increase with 196,370,600 shares, from 1,175,179,689 shares to 1,371,550,289 shares. In the event that all warrants of series TO3 are exercised, the dilution amounts to approximately 14.32 percent of the number of existing shares in the Company.

 

Please note that warrants that are not exercised on or before November 16, 2023, or sold on or before November 13, 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

 

How warrants are exercised:

Nominee-registered warrants (Custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

 

Direct-registered warrants (Securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

 

The application form including instructions for payment will be available at the Company’s website, www.peptonicmedical.se, and on Mangold Fondkommission AB’s website, www.mangold.se.

 

Advisers

Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the utilization of the warrants of series TO3.

 

 

 

For further information, please contact:

Erik Sundquist, CEO

Phone: + 46 722 49 90 43

Email: [email protected]

 

 

About PEPTONIC medical AB

Peptonic Medical AB is an innovative Swedish biomedical company engaged in research, development, and sales of unique medical treatments in the field of women's intimate health. Under the brand VagiVital®, the product portfolio encompasses treatments for various conditions such as vaginal atrophy, bacterial vaginosis, and urinary tract infections. These clinically tested products address the growing demand for intimate self-care within the business concept of Diagnose, Treat, Prevent. Sweden serves as the reference market to facilitate geographic expansion in collaboration with local distributors. The United States is the largest market in terms of sales. The company is headquartered in Stockholm, Sweden, with a sales office in New York, NY, and an R&D unit in Caesarea, Israel. Peptonic Medical also has a wholly owned subsidiary, Lune Oy, in Finland, focusing on sustainable period products sold under the Lunette®️ brand (www.lunette.com). The company's shares have been listed on www.spotlightstockmarket.com since 2014.

 

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

 

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.